Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions

International Journal of Clinical Practice

Volumn 61, Issue 3, 2007, Pages 444-448

  Li, Chang Sheng ^a   Cheng, B C ^a   Ge, W ^a   Gao, J F ^b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CYTOKERATIN 19 FRAGMENT; NEURON SPECIFIC ENOLASE; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD LEVEL; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PLEURA EFFUSION; PLEURA FLUID; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CA-125 ANTIGEN; CA-15-3 ANTIGEN; CA-19-9 ANTIGEN; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; KERATINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHOPYRUVATE HYDRATASE; PLEURAL EFFUSION; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 33847045987     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01111.x     Document Type: Article

References (17)

1. Right RW, ed. Pleural Diseases, Vol. 1, 3rd edn. Baltimere: Williams and Wilkins, 1995: 35-116.
2. Pavesi F, Lotzniker M, Cremaschi P et al. Detection of malignant pleural effusions by tumor marker evaluation. Eur J Cancer Clin Oncol 1988; 24: 1005-11.
3. Kim YC, Lim SC, Bom HS et al. Different cutoff values of CYFRA 21-1 for cavitary and noncavitary lung cancers. Lung Cancer 2000; 30: 187-92.
4. Muraki M, Tohda Y, Iwanaga T et al. Assessment of serum CYFRA 21-1 in lung cancer. Cancer 1996; 27: 1274-77.
5. Kalomenidis I, Dimakou K, Kolintza A et al. Sputum carcinoembryonic antigen, neuron-specific enolase and cytokeratin fragment19 levels in lung cancer diagnosis. Respirology 2004; 9: 54-9.
6. Nieder C, Andrats N, Jeremic B et al. Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer. Anticancer Res 2003; 23: 5117- 23.
7. Salama G, Miedouge M, Rouzaud P et al. Evaluation of pleural CYFRA 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions. Br J Cancer 1998; 77: 472-6.
8. Deisomritrutai W, Senawong S, Promkiamon B. Diagnostic utility of CYFRA21-1 in malignant pleural effusion. Respirology 2001; 6: 213-6.
9. Ferrer J, Villarino MA, Encabo G et al. Diagnostic utility of CYFRA21- 1, carcinoembryonic antigen, CA125, NSE, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions. Cancer 1999; 86: 1488-95.
10. Alatas F, Alatas O, Metintas M et al. Diagnostic value of CEA, CA15-3, CA19-9, CYFRA21-1, NSE and TSA assay in pleural effusions. Lung Cancer 2001; 31: 9-16.
11. Ustum H, Borazan A, Bilgicli N et al. Diagnostic value of tumoral markers in pleural effusions. Int J Clin Pract 2004; 58: 22-5.
12. Villena V, Lopez-Encuentra A, Echave-Sustaeta J et al. Diagnostic value of CA72-4, carcinoembryonic antigen, CA15-3, and CA19-9 assay in pleural fluid. A study of 10 patients. Cancer 1996; 78: 736-40.
13. Villena V, Lopez-Encuentra A, Echave-Sustueta J et al. Diagnostic value of CA549 in pleural fluid. Comparison with CEA, CA15-3 and CA72-4. Lung Cancer 2003; 40: 289-94.
14. Romero S, Fernandez C, Arriero JM et al. CEA, CA15-3 and CYFRA 21-1 in serum and pleural fluid of patients with pleural effusions. Eur Respir J 1996; 9: 17-23.
15. Ando S, Kimura H, Iwai N et al. Positive reactions for both CYFRA21-1 and CA125 indicate worst prognosis in NSCLC. Anticancer Res 2003; 23: 2869-74.
16. Kuralag F, Tokog Z, Comlekci A. Diagnostic usefulness of tumor marker levels in pleural effusions of malignant and benign origin. Clin Chim Acta 2000; 30: 43-55.
17. Miedouge M, Rouzaud P, Salarna G et al. Evaluation of seven tumor markers in pleural fluid for the diagnosis of malignant effusions. Br J Cancer 1999; 81: 1059.